Literature DB >> 10416617

Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.

M Kornmann1, K D Danenberg, N Arber, H G Beger, P V Danenberg, M Korc.   

Abstract

Cyclin D1 belongs to a family of protein kinases that have been implicated in cell cycle regulation. Inhibition of cyclin D1 expression has been recently shown (M. Kornmann, et al., J. Clin. Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum. The aim of the present study was to determine whether inhibition of cyclin D1 expression also modulates the effects of other antineoplastic drugs and whether it is associated with alterations in the level of expression of drug resistance genes. The suppression of cyclin D1 expression after the stable transfection of a cyclin D1 antisense construct in PANC-1 and COLO-357 human pancreatic cancer cells resulted in a significant increase in sensitivity to the fluoropyrimidines 5-fluorouracil and 5-fluoro-2'-deoxyuridine and to mitoxantrone. All of the antisense-expressing dones exhibited a decrease in thymidylate synthase and an increase in thymidine phosphorylase mRNA expression as determined by reverse transcription-PCR analysis and decreased levels of MDR-1 and MRP mRNA as determined by Northern blotting. These findings demonstrate that the inhibition of cyclin D1, in addition to suppressing the growth of pancreatic cancer cells, enhances their responsiveness to multiple chemotherapeutic agents and suggest that this effect may be due to the altered expression of several chemoresistance genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416617

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.

Authors:  Yehua Shen; Yan Pan; Litao Xu; Lianyu Chen; Luming Liu; Hao Chen; Zhen Chen; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2015-02-27

2.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.

Authors:  Bokyung Sung; Ajaikumar B Kunnumakkara; Gautam Sethi; Preetha Anand; Sushovan Guha; Bharat B Aggarwal
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

3.  Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation.

Authors:  Lin-Hai Yan; Xiao-Tong Wang; Jie Yang; Chao Lian; Fan-Biao Kong; Wei-Yuan Wei; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

Review 4.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

5.  CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.

Authors:  Sara Bar-Yehuda; Lea Madi; Daniel Silberman; Slosman Gery; Maya Shkapenuk; Pnina Fishman
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

6.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

7.  Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.

Authors:  Xiao-Ming Shuai; Gao-Xiong Han; Guo-Bin Wang; Jun-Hua Chen
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

8.  Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.

Authors:  Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Heinz Becker; Gustavo-B Baretton; Daniela-E Aust
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

9.  Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells.

Authors:  M E Laurance; D B Starr; E F Michelotti; E Cheung; C Gonzalez; A W Tam; J Deikman; C A Edwards; A J Bardwell
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

10.  Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth.

Authors:  S J Deharvengt; J R Gunn; S B Pickett; M Korc
Journal:  Cancer Gene Ther       Date:  2009-10-23       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.